NYSE:IQV - Iqvia Stock Price, News, & Analysis

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings data on Thursday, February, 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.47 by $0.03. The medical research company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.40 EPS. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Iqvia.

Iqvia will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8009094261.

Iqvia issued an update on its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share (EPS) guidance of $6.20-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.28. The company issued revenue guidance of $10.9-11.25 billion, compared to the consensus revenue estimate of $10.91 billion.Iqvia also updated its FY 2019 guidance to $6.20-6.40 EPS.

17 Wall Street analysts have issued 12 month price objectives for Iqvia's shares. Their predictions range from $120.00 to $170.00. On average, they expect Iqvia's stock price to reach $147.20 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Iqvia.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

News coverage about IQV stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), NIC (EGOV), Workday (WDAY) and Aegean Marine Petroleum Network (ANW).

Iqvia's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ardevora Asset Management LLP (0.14%), Strs Ohio (0.14%), Arvest Bank Trust Division (0.11%), Braun Stacey Associates Inc. (0.06%), Jag Capital Management LLC (0.06%) and DNB Asset Management AS (0.06%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Meeder Asset Management Inc., Arvest Bank Trust Division, DNB Asset Management AS, Retirement Systems of Alabama, Oakbrook Investments LLC, Telos Capital Management Inc. and Braun Stacey Associates Inc.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, Columbus Circle Investors, Jag Capital Management LLC, Pennsylvania Trust Co, Pennsylvania Trust Co, Nisa Investment Advisors LLC, Rosenblum Silverman Sutton S F Inc. CA and Deltec Asset Management LLC. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $137.36.

Iqvia has a market capitalization of $27.17 billion and generates $10.41 million in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.

The official website for Iqvia is http://www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BLVD., DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]